Why the study?
Do antiplatelet agents (aspirin, indomethacin) improve the course of vasotonic angina pectoris?
Do antiplatelet agents (aspirin, indomethacin) improve the course of vasotonic angina pectoris?
Thromboxane A2 is unlikely to be the primary cause of vasotonic angina, although it may be released secondarily during coronary vasospasm.
Answers are grounded in this paper and cite their sources.
Does not support antiplatelet use in vasotonic angina; leaves open thromboxane A2 as primary mediator.
Thromboxane A2 (TxA2), an arachidonic acid metabolite causing vasoconstriction and platelet aggregation, is a putative mediator of coronary-artery vasospasm. To determine whether platelet-released TxA2 causes coronary arterial vasospasm, we measured plasma thromboxane B2 (TxB2, the inactive hydration product of TxA2) in the radial-artery and coronary-sinus blood of seven patients and performed therapeutic trials of antiplatelet agents in nine. Although coronary-sinus TxB2 levels rose from the base line approximately fivefold with spontaneous ischemia, samples drawn early in ischemia showed no rise over base-line values. Although a 150 mg dose of aspirin reduced urinary dinor-TxB2 levels by over 75 per cent, it had no effect on the course of the chronic recurrent form of angina pectoris due to vasospasm ("vasotonic angina"). Similarly, indomethacin had no effect on the frequency or duration of ischemia. TxA2 is unlikely to cause vasotonic angina, but it may be released during coronary vasospasm.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: